SCHEMBL23696355

SCHEMBL23696355

COc1ccc(CCCC2CCN(Cc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SSTR5 P35346 2/20 0.61
HRH1 P35367 5/20 0.60
KCNH2 Q12809 5/20 0.60
CYP2D6 P10635 3/20 0.60
CHRM1 P11229 3/20 0.60
EED O75530 2/20 0.60
TACR2 P21452 2/20 0.60
TACR1 P25103 2/20 0.60
LMNA P02545 2/20 0.60
GAA P10253 2/20 0.60
TP53 P04637 2/20 0.60
SMN1; SMN2 Q16637 2/20 0.60
MEN1 O00255 1/20 0.60
MLNR O43193 1/20 0.60
CACNA1F O60840 1/20 0.60
USP2 O75604 1/20 0.60
ABCB11 O95342 1/20 0.60
EGFR P00533 1/20 0.60
HLA-A P04439 1/20 0.60
ERBB2 P04626 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23696353 0.95 SSTR5 (0.63) SSTR5HRH1KCNH2CYP2D6CHRM1
SCHEMBL23696356 0.88 CYP2D6 (0.57) SSTR5HRH1KCNH2CYP2D6CHRM1
SCHEMBL23696818 0.87 HRH1 (0.62) SSTR5HRH1KCNH2CYP2D6CHRM1
SCHEMBL23696357 0.86 LMNA (0.56) SSTR5HRH1KCNH2CYP2D6CHRM1
SCHEMBL23696354 0.85 SSTR5 (0.51) SSTR5HRH1KCNH2CYP2D6CHRM1
SCHEMBL23696819 0.85 HRH1 (0.69) SSTR5HRH1KCNH2CYP2D6CHRM1
SCHEMBL4142354 0.85 LMNA (0.61) LMNAMAPTDRD2DRD4OPRM1
SCHEMBL25570190 0.85 SSTR5 (0.51) SSTR5HRH1KCNH2CYP2D6CHRM1
SCHEMBL9540175 0.85 KCNH2 (0.71) SSTR5HRH1KCNH2CYP2D6CHRM1
SCHEMBL4152111 0.83 GRM2 (0.58) DRD2DRD4DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11667666-B2 Methods and compositions for treatment of cancer CFD RESEARCH CORPORATION (US) 2023-06-06 US disclosed
US-11667666-B2 Methods and compositions for treatment of cancer CFD RESEARCH CORPORATION (US) 2023-06-06 US disclosed
US-20210230212-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER CFD RESEARCH CORPORATION 2021-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11667666-B2 Methods and compositions for treatment of cancer TEK, VHL, TIE1 SSTR5 1626/4885HRH1 4358/4885KCNH2 4843/4885
US-20210230212-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER TEK, VHL, TIE1 SSTR5 1626/4885HRH1 4358/4885KCNH2 4843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.